Cargando…

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment

Recently there has been a significant progression in the understanding of molecular mutations driving biochemical and cellular signaling changes leading to survival and proliferation of leukemia cells in patients with acute myeloid leukemia (AML). Preclinical studies have demonstrated a mutated enzy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reed, Daniel R, Elsarrag, Ramey Z, Morris, Amy L, Keng, Michael K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724422/ https://www.ncbi.nlm.nih.gov/pubmed/31564968 http://dx.doi.org/10.2147/CMAR.S162784

Ejemplares similares

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
por: Galkin, Maria, et al.
Publicado: (2019)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
por: Kim, Yundeok, et al.
Publicado: (2020)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
por: Pollyea, Daniel A., et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

Challenges of Fertility Sparing Ovarian Surgery Imposed by Krukenberg Tumors in Pregnancy
por: Bloch, Michael H., et al.
Publicado: (2015)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
por: Annamaraju, Pavan, et al.
Publicado: (2020)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application
por: Li, Shuang-long, et al.
Publicado: (2020)

Epidemiology of acute myeloid leukemia in Virginia: Excellent survival outcomes for patients in rural Appalachia
por: Isaac, Krista M., et al.
Publicado: (2021)

Developments in chemotherapy for the treatment of acute myeloid leukemia
por: Drummond, Mark W
Publicado: (2019)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Development of treatment and clinical results in childhood acute myeloid leukemia in Poland
por: Balwierz, Walentyna, et al.
Publicado: (2012)

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment
por: Li, Yan, et al.
Publicado: (2019)

Early Ophthalmological Manifestations of Acute Myeloid Leukemia: Current Perspectives
por: El Salloukh, Nasrine Anais, et al.
Publicado: (2022)

The Patient Perspective on Living with Acute Myeloid Leukemia
por: Tomaszewski, Erin L., et al.
Publicado: (2016)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Current perspectives for the treatment of chronic myeloid leukemia
por: ALADAĞ, Elifcan, et al.
Publicado: (2019)

Unexplained pancytopenia in acute myeloid leukemia treatment
por: Ezekwudo, Daniel, et al.
Publicado: (2018)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
por: Pinto-Merino, Álvaro, et al.
Publicado: (2022)

Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007)

Treatment of Relapsed Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2020)

UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics
por: Wang, Bo-wen, et al.
Publicado: (2021)

Chronic myeloid leukemia developing in treated acute promyelocytic leukemia
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

CAMKs support development of acute myeloid leukemia
por: Kang, Xunlei, et al.
Publicado: (2018)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

Targeted Therapy Development in Acute Myeloid Leukemia
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives
por: Damiani, Daniela, et al.
Publicado: (2023)

Myeloid Sarcoma in an Eyelid That Developed during Chemotherapy for Acute Myeloid Leukemia
por: Kang, Hyera, et al.
Publicado: (2016)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

DPP8/9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia
por: Johnson, Darren C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_28hs18ij87v866eb0n90mj4n2r